Literature DB >> 582791

Pharmacokinetics of vinpocetine in humans.

L Vereczkey, G Czira, J Tamás, Z Szentirmay, Z Botár, L Szporny.   

Abstract

The pharmacokinetics of ethyl-apovincaminate (vinpocetine, Cavinton), a new vincamine derivative has been studied in volunteers after p.o. and i.v. administration. The concentration of the drug was determined by mass-fragmentography in human plasma. There was a biphasic elimination of the substance after i.v. injection with a T1/2 alpha of 0.136 h and with a T1/2 beta of 4.83 h. The value of Vdss (2.1 l/kg) shows a high adsorption of the drug by tissue proteins. The clearance rate of elimination was 0.366 l/h/kg. Oral administration of the drug resulted in maximum plasma concentration 1--1.5 h after the administration with values of 20--62 ng/ml. The bioavailability of the drug--calculated from the ratio of the areas under the concentration-time curves--proved to be 56.6 +/- 8.9%. Unchanged vinpocetine could not be detected in urine. From the results two-compartment open models were constructed and the steady state concentrations after multiple dosing were computed.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 582791

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  9 in total

1.  Nano-advantage in enhanced drug delivery with biodegradable nanoparticles: contribution of reduced clearance.

Authors:  Rajendra S Kadam; David W A Bourne; Uday B Kompella
Journal:  Drug Metab Dispos       Date:  2012-04-12       Impact factor: 3.922

Review 2.  Pharmacology of nootropics and metabolically active compounds in relation to their use in dementia.

Authors:  C D Nicholson
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

3.  Pharmacokinetics of vinpocetine and its main metabolite apovincaminic acid before and after the chronic oral administration of vinpocetine to humans.

Authors:  P Miskolczi; K Kozma; M Polgár; L Vereczkey
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Jan-Mar       Impact factor: 2.441

Review 4.  Pharmacokinetics and metabolism of vincamine and related compounds.

Authors:  L Vereczkey
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1985 Apr-Jun       Impact factor: 2.441

5.  Clinical plasma concentration of vinpocetine does not affect osteogenic differentiation of mesenchymal stem cells.

Authors:  Esma Yıldırım; Gulay Sezer
Journal:  Pharmacol Rep       Date:  2020-08-31       Impact factor: 3.024

6.  The metabolic fate of 11-bromo[15-3H]vincamine in man.

Authors:  B C Mayo; S R Biggs; D R Hawkins; L F Chasseaud; A Darragh; F C Leaf
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1985 Jul-Sep       Impact factor: 2.441

7.  Systemic exposure of vinpocetine in pregnant Sprague Dawley rats following repeated oral exposure: An investigation of fetal transfer.

Authors:  Suramya Waidyanatha; Heather Toy; Natalie South; Seth Gibbs; Esra Mutlu; Brian Burback; Barry S McIntyre; Natasha Catlin
Journal:  Toxicol Appl Pharmacol       Date:  2017-11-15       Impact factor: 4.219

8.  Effect of age on the pharmacokinetics of vinpocetine (Cavinton) and apovincaminic acid.

Authors:  P Miskolczi; L Vereczkey; L Szalay; C Göndöc
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

9.  Personalized medicine: Vinpocetine to reverse effects of GABRB3 mutation.

Authors:  Santoshi Billakota; J Michael Andresen; Bryant C Gay; Gregory R Stewart; Nikolai B Fedorov; Aaron C Gerlach; Orrin Devinsky
Journal:  Epilepsia       Date:  2019-11-22       Impact factor: 5.864

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.